Congress Materials – Fall Clinical Dermatology Conference (FCDC 2026)
2026 Fall Clinical Dermatology Conference | Oct 8-11 | Las Vegas, NV
Durability of Icotrokinra Effect in Participants With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Pooled Analysis of One-Year Outcomes From the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials
April W. Armstrong, Iain B. McInnes, Linda Stein Gold, Mark G. Lebwohl, Ofelia Reyes-Servin, Ya-Wen Yang, Soumya D. Chakravarty, Charles Iaconangelo, Kellen Cresswell, Tasneam Shagroni, Sarah Ofori, Karissa Lozenski, Joseph F. Merola
Durability of Response to Icotrokinra in Adults and Adolescents With Moderate-to-Severe Plaque Psoriasis: 2-Year ICONIC-LEAD Findings
Robert Bissonnette, Jennifer Soung Andrew E. Pink, Darryl P. Toth, Andreas Pinter, Angela Y. Moore, Amy Paller, Kilian Eyerich, Jingzhi Jiang, Ya-Wen Yang, Megan Miller-Kassamali, Cynthia M.C. DeKlotz, Shu Li, Mark G. Lebwohl
Durability of Systemic and Skin Pharmacodynamic Responses With Icotrokinra in Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Week 52 Results
J Angsana, C Hill, E Chen, S Nischal, D Balakrishna, L Tomsho, ME Polak, C Sisk, A Kannan, C DeKlotz, M Miller-Kassamali, (REMOVE: J Cafone), Y-W Yang, P Newbold, CA Cuff, D Waterworth, N Sabins, JG Krueger, A Pinter, R Bissonnette
Effects of Glucagon-Like Peptide-1 (GLP-1)–Based Medications on Icotrokinra Efficacy, Safety, and Pharmacokinetics: Pooled Results Across ICONIC Phase 3 Studies
Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Andrew E. Pink, Lea Kephart, Bassey Effiom Edem, Ofelia Reyes-Servin, Shu Li, Ya-Wen Yang, Christopher Russo, Benjamin Ungar, Mark G. Lebwohl
Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, April W. Armstrong, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
Durability and Safety of the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 2-Year ICONIC-TOTAL Findings
Richard B. Warren, Eingun James Song, Edward Lain, Joseph F. Merola, Matthias Hoffmann, Robert Bissonnette, Yu-Huei Huang, Amy Paller, Jessica H. Rubens, Melissa Larick, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Cynthia M. C. DeKlotz, Melinda Gooderham
Patient Preferences for Systemic Psoriasis Treatments: Initial findings from a multi-country Discrete Choice Experiment
Jennifer Soung, Linda Stein Gold, Ellen Janssen, Hui Lu, Christine Michaels-Igbokwe, Tim Fitzgerald, Jensen Lewis, Torben Kasparek, Guo Li, Mona Shahriari
Prior Treatment Patterns, Clinical Characteristics, and Disease Burden Among Patients Initiating Icotrokinra
Hsien-Yen Chang, Alexander Litvintchouk, Cindy Chen, Timothy Fitzgerald, Christine Cornejo, Steve Feldman
Unmet Needs and Disease Burden: Perspectives from Adults with Psoriasis and Clinicians treating Psoriasis in Brazil
Ricardo Romiti, Linda Stein Gold, Jennifer Soung, Melina Taylor, Ashley Duenas, Jensen Lewis, Choo Hua Goh, Gale Harding, Torben Kasparek, Guo Li, Mona Shahriari
VISIBLE Cohort A: Guselkumab Skin Clearance and Patient-Reported Outcomes Across Skin and Joint Symptoms Through Week 100 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones
Andrew Alexis, Adrian O Rodriguez, Geeta Yadav, Stephen K Tyring, Olivia Choi, Theodore Alkousakis, Daphne Chan, Tony Ma, Maxwell Sauder, Javier Alonso-Llamazares, Seemal R Desai
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.